Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
*Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
2024年7月30日，伊頓製藥公司（"伊頓" 或"公司"）（納斯達克：ETON），一家專注於開發和商業化罕見病治療方法的創新藥企，今天宣佈將於2024年8月8日星期四發佈2024年第二季度財務業績。管理層將於東部時間下午4:30（中部時間下午3:30）舉行電話會議和現場音頻網絡會議，討論業績。
| Dial in* (Audio Only) | Click Here |
| Webcast: | Click Here |
| 僅限電話撥入*（僅音頻） | 點擊這裏 |
| 網絡直播： | 點擊這裏 |
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
除了在電話會議上回答參會人員的實時提問外，管理層還將回答投資者在電子郵件中發送的問題。投資者可以將問題發送到：investorrelations@etonpharma.com。
The live webcast can also be accessed on the Investors section of Eton's website at . An archived webcast will be available on Eton's website approximately two hours after the completion of the event and for 30 days thereafter.
現場網絡直播也可以在伊頓製藥公司的投資者板塊上獲得。活動完成後約兩個小時，伊頓製藥公司網站上將有存檔網絡直播，存檔時間爲30天。
*Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.
*電話會議參與者應進行註冊，以獲取電話撥入和密碼詳細信息。請務必使用有效的電子郵件地址進行註冊。
About Eton Pharmaceuticals
關於伊頓製藥公司
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. For more information, please visit our website at .
伊頓是一家專注於研發和商業化罕見病治療的創新性製藥公司。該公司目前擁有五種罕見病產品：ALKINDI SPRINKLE，PKU GOLIKE，Carglumic Acid，Betaine Anhydrous和Nitisinone。公司目前處於三個尾期開發的產品，包括ET-400，ET-600和ZENEO水楊酸巴利昂自動注射器。欲了解更多信息，請訪問我公司網站。
Investor Relations:
投資者關係:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Lisa m. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals
來源：伊頓製藥公司
Source: Eton Pharmaceuticals
來源：伊頓製藥公司
譯文內容由第三人軟體翻譯。